A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples